Tag - PEPG

Developments

PepGen reveals positive initial Phase 1 study results of PGN-EDODM1 in DM1

PepGen (NASDAQ:PEPG) has announced initial positive data from the five and ten mg/kg dose cohorts in its ongoing FREEDOM-DM1 Phase 1 study investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1). PeoGen reports that...

February 24, 2025

Markets

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

May 31, 2022

Tag - PEPG

PepGen reveals positive initial Phase 1 study results of PGN-EDODM1 in DM1

SVB Securities starts PepGen at OP; PT $40

Subscribe